Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery

NCT05149495 | Unknown

• 1 other identifier: 8409
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basis of his experience and knowledge of the patient, the long-term course with somatostatin analogues being very little described. Thus, although hormonal control is achieved in a majority of cases under medical treatment, we do not know if it is possible to stop treatment and in this case how the pathology evolves. It would appear that approximately 40% of patients defined as very good responders to somatostatin analogues may gradually space their injections.

Conditions

Acromegaly

Keywords

Acromegaly; Pituitary microadenoma; Pituitary macroadenoma; Somatostatin analogues; Hormonal control

Outcome Measures

Primary Outcomes (1)

• Study of the clinical and biological evolution, after discontinuation of treatment with somatostatin analogues, of acromegalic patients with recurrence after surgery.

  Files analysed retrospectively from January 01, 2000 to September 01, 2021 will be examined]

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subject operated for a pituitary adenoma at the HUS between 01/01/2000 to 09/01/2021

You may qualify if:

• Major subject (≥18 years old)
• Having been seen at least once in consultation in the Internal Medicine, Endocrinology and Nutrition department of Hautepierre Hospital
• Subject operated for a pituitary adenoma at the HUS between 01/01/2000 to 09/01/2021
• In whom biological confirmation of recurrence has been demonstrated
• Patient not having expressed his opposition, after information, to the reuse of his data for scientific research purposes.

You may not qualify if:

• Subject having expressed opposition to participating in the study
• Treatment pre and / or post surgery by radiotherapy
• No recurrence
• No treatment with a somatostatin analogue for recurrence
• Subject under guardianship, curatorship or safeguard of justice

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service Médecine Interne, Endocrinologie et Nutrition - Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Acromegaly

Condition Hierarchy (Ancestors)

Bone Diseases, Endocrine; Bone Diseases; Musculoskeletal Diseases; Hyperpituitarism; Pituitary Diseases; Hypothalamic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Endocrine System Diseases

Study Officials

• Philippe BALTZINGER, MD

  Service Médecine Interne, Endocrinologie et Nutrition - Hôpitaux Universitaires de Strasbourg

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Philippe BALTZINGER, MD

CONTACT

33 3 88 12 75 82; philippe.baltzinger@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

said.chayer@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2021
• First Posted: December 8, 2021
• Study Start: October 1, 2021
• Primary Completion: March 1, 2023
• Study Completion: March 20, 2023
• Last Updated: December 8, 2021

Record last verified: 2021-11

Locations

FR (1)